FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045136195> ?p ?o ?g. }

• W3045136195 endingPage "1878" @default.
• W3045136195 startingPage "1870" @default.
• W3045136195 abstract "Abstract Purpose To investigate the safety and efficacy of dabrafenib and trametinib combination therapy for BRAF V600 mutation-positive unresectable and metastatic melanoma in over 100 Japanese patients of a real-world clinical setting. Patients The surveillance period of interim post-marketing surveillance (PMS) analysis was from June 2016 to November 2018, and 112 patients with unresectable and metastatic BRAF V600 melanoma who received dabrafenib and trametinib were enrolled. Results The safety analysis set included 112 patients whom almost all patients had stage IV disease ( n = 97, 86.61%) with an Eastern Cooperative Oncology Group performance status 0 or 1 ( n = 102, 91.07%), and mean (standard deviation) lactate dehydrogenase level was 354.3 (456.4) U/L ( n = 105) at baseline. Median daily dose of dabrafenib was 300.0 mg/day (118–300), and median daily dose of trametinib was 2.00 mg/day (1.0–4.0). Adverse drug reactions (ADRs) were reported in 84 patients (75%), and common ADRs (incidence ≥ 5%) were pyrexia ( n = 49, 43.75%), hepatic function abnormal ( n = 11, 9.82%), rash and blood creatine phosphokinase increased ( n = 9 each, 8.04%), and erythema nodosum ( n = 6, 5.36%). Majority of ADRs reported in this study were consistent with that reported in previous trials. In the efficacy analysis set of 110 patients, the objective response rate was 55.45% (95% confidence interval 45.67–64.93%), and median progression-free survival was 384.0 days (251.0 days-not reached). Conclusions No new safety or efficacy concerns were observed in this interim PMS analysis in Japanese patients with unresectable and metastatic melanoma with BRAF gene mutation who received dabrafenib and trametinib combination therapy." @default.
• W3045136195 created "2020-07-29" @default.
• W3045136195 creator A5010531275 @default.
• W3045136195 creator A5037480032 @default.
• W3045136195 creator A5064058441 @default.
• W3045136195 creator A5067594256 @default.
• W3045136195 creator A5089954129 @default.
• W3045136195 date "2020-07-22" @default.
• W3045136195 modified "2023-10-01" @default.
• W3045136195 title "Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation" @default.
• W3045136195 cites W1916356108 @default.
• W3045136195 cites W1971475476 @default.
• W3045136195 cites W1997304962 @default.
• W3045136195 cites W2019607817 @default.
• W3045136195 cites W2037396390 @default.
• W3045136195 cites W2056199226 @default.
• W3045136195 cites W2094848657 @default.
• W3045136195 cites W2096575630 @default.
• W3045136195 cites W2111863560 @default.
• W3045136195 cites W2160766792 @default.
• W3045136195 cites W2162044478 @default.
• W3045136195 cites W2295382849 @default.
• W3045136195 cites W2620403292 @default.
• W3045136195 cites W2791686077 @default.
• W3045136195 cites W2948155539 @default.
• W3045136195 doi "https://doi.org/10.1007/s10147-020-01737-3" @default.
• W3045136195 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7498495" @default.
• W3045136195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32699976" @default.
• W3045136195 hasPublicationYear "2020" @default.
• W3045136195 type Work @default.
• W3045136195 sameAs 3045136195 @default.
• W3045136195 citedByCount "5" @default.
• W3045136195 countsByYear W30451361952020 @default.
• W3045136195 countsByYear W30451361952022 @default.
• W3045136195 countsByYear W30451361952023 @default.
• W3045136195 crossrefType "journal-article" @default.
• W3045136195 hasAuthorship W3045136195A5010531275 @default.
• W3045136195 hasAuthorship W3045136195A5037480032 @default.
• W3045136195 hasAuthorship W3045136195A5064058441 @default.
• W3045136195 hasAuthorship W3045136195A5067594256 @default.
• W3045136195 hasAuthorship W3045136195A5089954129 @default.
• W3045136195 hasBestOaLocation W30451361952 @default.
• W3045136195 hasConcept C121608353 @default.
• W3045136195 hasConcept C126322002 @default.
• W3045136195 hasConcept C141071460 @default.
• W3045136195 hasConcept C143998085 @default.
• W3045136195 hasConcept C184235292 @default.
• W3045136195 hasConcept C197934379 @default.
• W3045136195 hasConcept C2776131300 @default.
• W3045136195 hasConcept C2777658100 @default.
• W3045136195 hasConcept C2778472372 @default.
• W3045136195 hasConcept C2778570526 @default.
• W3045136195 hasConcept C2778830669 @default.
• W3045136195 hasConcept C2994587330 @default.
• W3045136195 hasConcept C502942594 @default.
• W3045136195 hasConcept C535046627 @default.
• W3045136195 hasConcept C57074206 @default.
• W3045136195 hasConcept C61943457 @default.
• W3045136195 hasConcept C71924100 @default.
• W3045136195 hasConcept C86803240 @default.
• W3045136195 hasConcept C90924648 @default.
• W3045136195 hasConcept C95444343 @default.
• W3045136195 hasConceptScore W3045136195C121608353 @default.
• W3045136195 hasConceptScore W3045136195C126322002 @default.
• W3045136195 hasConceptScore W3045136195C141071460 @default.
• W3045136195 hasConceptScore W3045136195C143998085 @default.
• W3045136195 hasConceptScore W3045136195C184235292 @default.
• W3045136195 hasConceptScore W3045136195C197934379 @default.
• W3045136195 hasConceptScore W3045136195C2776131300 @default.
• W3045136195 hasConceptScore W3045136195C2777658100 @default.
• W3045136195 hasConceptScore W3045136195C2778472372 @default.
• W3045136195 hasConceptScore W3045136195C2778570526 @default.
• W3045136195 hasConceptScore W3045136195C2778830669 @default.
• W3045136195 hasConceptScore W3045136195C2994587330 @default.
• W3045136195 hasConceptScore W3045136195C502942594 @default.
• W3045136195 hasConceptScore W3045136195C535046627 @default.
• W3045136195 hasConceptScore W3045136195C57074206 @default.
• W3045136195 hasConceptScore W3045136195C61943457 @default.
• W3045136195 hasConceptScore W3045136195C71924100 @default.
• W3045136195 hasConceptScore W3045136195C86803240 @default.
• W3045136195 hasConceptScore W3045136195C90924648 @default.
• W3045136195 hasConceptScore W3045136195C95444343 @default.
• W3045136195 hasFunder F4320332736 @default.
• W3045136195 hasIssue "10" @default.
• W3045136195 hasLocation W30451361951 @default.
• W3045136195 hasLocation W30451361952 @default.
• W3045136195 hasLocation W30451361953 @default.
• W3045136195 hasOpenAccess W3045136195 @default.
• W3045136195 hasPrimaryLocation W30451361951 @default.
• W3045136195 hasRelatedWork W125335819 @default.
• W3045136195 hasRelatedWork W1982776503 @default.
• W3045136195 hasRelatedWork W1996765884 @default.
• W3045136195 hasRelatedWork W2023835753 @default.
• W3045136195 hasRelatedWork W2040622041 @default.
• W3045136195 hasRelatedWork W2062175357 @default.
• W3045136195 hasRelatedWork W2116362236 @default.
• W3045136195 hasRelatedWork W2330163139 @default.
• W3045136195 hasRelatedWork W2413725987 @default.

• next